Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL

(2019) Magdalena Klanova et al.   BLOOD

Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse

(2019) Neta Goldschmidt et al.   LEUKEMIA & LYMPHOMA

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

(2019) Nancy L. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma

(2018) David Qualls et al.   HAEMATOLOGICA

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

(2017) Daniel J. Landsburg et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

(2016) K. J. Savage et al.   BLOOD

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

(2016) Christopher M. Melén et al.   BRITISH JOURNAL OF HAEMATOLOGY

Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model

(2016) Roopesh Kansara et al.   BRITISH JOURNAL OF HAEMATOLOGY

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

(2016) Norbert Schmitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

(2015) Tove Wästerlid et al.   HEMATOLOGICAL ONCOLOGY

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

(2014) C Y Cheah et al.   BRITISH JOURNAL OF CANCER

Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era

(2014) Andrés J. M. Ferreri et al.   BRITISH JOURNAL OF HAEMATOLOGY

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

(2014) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

(2014) W. H. Wilson et al.   HAEMATOLOGICA

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma

(2014) Idun Fiskvik et al.   LEUKEMIA & LYMPHOMA

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

(2013) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

(2013) David Cunningham et al.   LANCET

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

(2013) Richard Delarue et al.   LANCET ONCOLOGY

Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

(2013) Patrick J. Stiff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study

(2012) H. Holte et al.   ANNALS OF ONCOLOGY

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

(2012) Norbert Schmitz et al.   LANCET ONCOLOGY

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2011) N. Schmitz et al.   ANNALS OF ONCOLOGY

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

(2011) A. O. Gang et al.   ANNALS OF ONCOLOGY

Prevention of CNS relapse in diffuse large B-cell lymphoma

(2011) Robert Kridel et al.   LANCET ONCOLOGY

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

(2010) Jeremy S. Abramson et al.   CANCER

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

(2009) V. Boehme et al.   BLOOD

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

(2009) Sandra Quijano et al.   JOURNAL OF CLINICAL ONCOLOGY